⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835913 | 0.79 | ADRB3 (0.31) | — | |
| SCHEMBL9933480 | 0.79 | ADRB3 (0.31) | — | |
| SCHEMBL9933478 | 0.79 | ADRB3 (0.31) | — | |
| SCHEMBL15024230 | 0.79 | NOTUM (0.39) | — | |
| SCHEMBL4743084 | 0.76 | NOTUM (0.50) | — | |
| SCHEMBL12525098 | 0.71 | NOTUM (0.37) | — | |
| SCHEMBL10211146 | 0.67 | ALDH1A1 (0.46) | — | |
| SCHEMBL22730767 | 0.66 | — | — | |
| SCHEMBL15448165 | 0.66 | NOTUM (0.42) | — | |
| SCHEMBL23901475 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |